Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $19.37 $25.53 Friday, 10th May 2024 NTLA stock ended at $24.46. This is 1.61% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 4.85% from a day low at $24.25 to a day high of $25.42.
90 days $19.37 $34.87
52 weeks $19.37 $47.48

Historical Intellia Therapeutics Inc prices

Date Open High Low Close Volume
Jun 20, 2023 $44.48 $45.20 $43.58 $43.62 770 404
Jun 16, 2023 $46.41 $46.90 $44.83 $44.91 1 608 050
Jun 15, 2023 $44.50 $45.68 $44.38 $45.57 647 272
Jun 14, 2023 $46.72 $47.48 $43.71 $45.20 1 319 441
Jun 13, 2023 $44.24 $46.35 $44.09 $46.03 1 133 684
Jun 12, 2023 $44.20 $46.14 $43.11 $43.61 1 728 465
Jun 09, 2023 $44.61 $44.61 $42.69 $43.24 798 970
Jun 08, 2023 $43.40 $44.00 $42.60 $43.36 638 504
Jun 07, 2023 $43.88 $44.74 $43.02 $43.46 665 649
Jun 06, 2023 $41.26 $43.76 $41.14 $43.62 990 069
Jun 05, 2023 $40.67 $41.71 $40.51 $41.27 852 012
Jun 02, 2023 $38.88 $41.05 $38.56 $40.96 985 264
Jun 01, 2023 $37.44 $38.53 $36.62 $38.16 595 768
May 31, 2023 $37.27 $38.65 $36.59 $37.26 1 150 462
May 30, 2023 $39.17 $39.90 $37.07 $37.55 1 085 998
May 26, 2023 $38.74 $39.42 $38.01 $38.98 751 581
May 25, 2023 $41.65 $41.65 $38.90 $39.22 1 165 837
May 24, 2023 $42.79 $43.29 $41.27 $41.76 911 273
May 23, 2023 $44.42 $45.64 $43.29 $43.45 894 703
May 22, 2023 $42.01 $44.48 $41.95 $44.39 1 186 621
May 19, 2023 $43.43 $43.62 $41.68 $42.02 1 030 191
May 18, 2023 $43.59 $43.59 $41.68 $42.96 991 180
May 17, 2023 $43.74 $44.17 $42.72 $43.80 873 734
May 16, 2023 $45.00 $45.06 $43.00 $43.70 1 089 030
May 15, 2023 $43.56 $46.98 $43.16 $45.76 1 295 208
Click to get the best stock tips daily for free!

About Intellia Therapeutics Inc

Intellia Therapeutics Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline... NTLA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT